ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ViiV and Janssen seek European approval for HIV two-drug regimen
July 31, 2019ViiV Healthcare and Janssen Pharmaceutical have filed separate marketing authorisation applications (MAA) for the use of their respective drugs, cabotegravir and rilpivirine, as a combination therapy in adults with HIV infection. -
ViiV Healthcare's Dovato approved in US as first two-drug single-tablet regimen for patients with treatment-naïve HIV
April 09, 2019The FDA on Monday announced the approval of ViiV Healthcare's Dovato (dolutegravir/lamivudine) for ^ -
ViiV's two-drug regimen gets EU approval for HIV-1
May 25, 2018ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the European Commission, making it the first available two-drug regimen, daily single pill solution for the type 1
Pharma Sources Insight January 2025
